MarginsXMarginsX
Home › Markets › Health Care › OGN

Organon & Co. Common Stock (OGN)

OGN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.90
0.00% on the day
Market cap
$3.7B
Mid cap
Revenue · 2025
$6.2B
-2.9% on 2024
Net income · 2025
$187.0M
3.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/0001628280-26-011125-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerOGN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001821825
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$6.2B
Net income$187.0M
Operating incomeNot in SEC XBRL data
Net margin3.0%
Operating marginOperating income not reported
Revenue growth-2.9%
Cash$574.0M
Total assets$12.9B
P/E (computed)19.5×
P/S (computed)0.6×

Warning signs

Cash runway
Cash-flow positive
$1.5B cash at September 30, 2026
Share count, 1 year
+1.0%
2025-11-03 to 2026-10-23 · +2.7% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
$301K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$1.5B cash; operating cash flow $210.8M a quarter.Report 2026-09-30
Shares outstanding262,621,584 (2026-10-23); 259,982,912 a year earlier; 255,606,461 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $855K, sold $553K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6B$164.0M$370.0M$1.5B$8.6B$6.1B10-Q 2026-10-30
Q2 2026
2026-06-30
$1.6B$108.0M$107.0M$1.1B$8.6B$6.1B10-Q 2026-07-31
Q1 2026
2026-03-31
$1.5B$146.0M$225.0M$1.1B$8.6B$6.2B10-Q 2026-05-04
Q4 2025
2025-12-31
$1.5B-$205.0M$141.0M$574.0M$8.6B$6.2B10-K 2026-02-24
Q3 2025
2025-09-30
$1.6B$160.0M$264.0M$672.0M$8.8B$6.3B10-Q 2026-10-30
Q2 2025
2025-06-30
$1.6B$145.0M$220.0M$599.0M$8.9B$6.3B10-Q 2026-07-31
Q1 2025
2025-03-31
$1.5B$87.0M$75.0M$547.0M$9.0B$6.3B10-Q 2026-05-04
Q4 2024
2024-12-31
$1.6B$109.0M$390.0M$675.0M$8.9B$6.4B10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentDRS2020-11-02
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-10-30
Latest current report
FORM 8-K
8-K2026-10-30
Latest proxyDEFA14A2026-07-17

Source: SEC EDGAR submissions feed, 466 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.2%
1 month+0.9%
3 months+1.3%
Year to date+93.9%
1 year+82.4%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
XENEXenon Pharmaceuticals Inc. Common Shares$39.26-3.01%$3.9B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier